| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Anticancer potential of metformin: focusing on gastrointestinal cancers
|
Khezri, Mohammad rafi
|
|
|
87 |
5 |
p. 587-598
|
article
|
| 2 |
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
|
Sarkar, Sunit
|
|
|
87 |
5 |
p. 613-620
|
article
|
| 3 |
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
|
Collier, Katharine A.
|
|
|
87 |
5 |
p. 599-611
|
article
|
| 4 |
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine
|
Liu, Duo
|
|
|
87 |
5 |
p. 681-687
|
article
|
| 5 |
Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk
|
Burns, Kathryn E.
|
|
|
87 |
5 |
p. 711-716
|
article
|
| 6 |
Detecting DPD deficiency: when perfect is the enemy of good
|
Ciccolini, Joseph
|
|
|
87 |
5 |
p. 717-719
|
article
|
| 7 |
Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis
|
Liu, Yang
|
|
|
87 |
5 |
p. 701-710
|
article
|
| 8 |
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
|
Gao, Ling
|
|
|
87 |
5 |
p. 635-645
|
article
|
| 9 |
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
|
Khosravan, Reza
|
|
|
87 |
5 |
p. 621-634
|
article
|
| 10 |
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway
|
Yi, Xianglan
|
|
|
87 |
5 |
p. 647-656
|
article
|
| 11 |
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
|
Ishibashi, Keiichiro
|
|
|
87 |
5 |
p. 665-672
|
article
|
| 12 |
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
|
Lynce, Filipa
|
|
|
87 |
5 |
p. 673-679
|
article
|
| 13 |
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population
|
Saarenheimo, Jatta
|
|
|
87 |
5 |
p. 657-663
|
article
|
| 14 |
Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level
|
Gong, Anjing
|
|
|
87 |
5 |
p. 721
|
article
|
| 15 |
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
|
Li, Chao
|
|
|
87 |
5 |
p. 689-700
|
article
|
Journal description